We are live on
!
Find out more
Denali Therapeutics
DNLI
DNLI
209 hedge funds and large institutions have $2.49B invested in Denali Therapeutics in 2023 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 72 increasing their positions, 68 reducing their positions, and 20 closing their positions.
New
Increased
Maintained
Reduced
Closed
100% more funds holding in top 10
Funds holding in top 10: 3 → 6 (+3)
85% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 20
23% more call options, than puts
Call options by funds: $1.82M | Put options by funds: $1.48M
11% more capital invested
Capital invested by funds: $2.24B → $2.49B (+$243M)
8% more funds holding
Funds holding: 194 → 209 (+15)
4.89% more ownership
Funds ownership: 79.06% → 83.95% (+4.9%)
6% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 68
Holders
209
Holders Change
+15
Holders Change %
+7.73%
% of All Funds
3.05%
Holding in Top 10
6
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+100%
% of All Funds
0.09%
New
37
Increased
72
Reduced
68
Closed
20
Calls
$1.82M
Puts
$1.48M
Net Calls
+$341K
Net Calls Change
-$1.02M
Top Buyers
| 1 |
Marshall Wace
London,
United Kingdom
|
+$33M |
| 2 |
State Street
Boston,
Massachusetts
|
+$24M |
| 3 |
Morgan Stanley
New York
|
+$19.3M |
| 4 |
BlackRock
New York
|
+$13M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$12.8M |
